---
category: news
title: "NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology"
excerpt: "Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality Assurance Company to host an investor webinar on"
publishedDateTime: 2022-10-12T13:01:00Z
originalUrl: "https://www.marketwatch.com/press-release/nurexone-signs-letter-of-intent-with-nanometrix-for-its-exosome-and-cargo-molecular-profiling-ai-driven-technology-2022-10-12"
webUrl: "https://www.marketwatch.com/press-release/nurexone-signs-letter-of-intent-with-nanometrix-for-its-exosome-and-cargo-molecular-profiling-ai-driven-technology-2022-10-12"
type: article
quality: 27
heat: 27
published: false

provider:
  name: MarketWatch
  domain: marketwatch.com
  images:
    - url: "https://everyday-cc.github.io/ai/assets/images/organizations/marketwatch.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI in Healthcare
  - AI

secured: "3zhz5FrCB35GwtMqRHr02ziq6KVH/02CJzhi+9Ai1sTbNoBPbr8Q3L6vrqPPReCJrUb7RdiXSt4HeCTh4J8YPDkMVIHceoLk9roOXXSC2gStDUt3HihLK4kE+noO/lnqvBro2JS6NSht3o4aZLf0bsyyuj9p/O61QJOqgy2VitNiMwiv80VJd/17mv3Po6IPXHDMNiW+AVwfGgSQj0o6eYnfzSPj+buWPKo9vKE8yR4b4R7U/qQls8hHHul1QpRYtTx198DPtUSFuzGz58aVlLjMa5F6RH8KHY90qUGcdLwN/hDPxQQCXZ34ynbsUky9oF5tRZvyvF8mtp3pfrcNVzgekEd8vk95vn3dbU5IkUk=;pK/XBDnbOH3bBDNpANgfeg=="
---

